Biogen's Aduhelm still has blockbuster potential if everything breaks right: analyst

Amid a torrent of negative press for Biogen’s troubled Alzheimer's disease treatment Aduhelm, there remains a significant community of patients and doctors who are hoping to use and prescribe the drug, a team of analysts found.